ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

William Sandborn  ¹     Severine Vermeire  ²     Laurent Peyrin-Biroulet  ³     Marla C. Dubinsky  ⁴     Julian Panés  ⁵     Andres Yarur  ⁶     Timothy Ritter  ⁷     Filip Baert  ⁸     Stefan Schreiber  ⁹     Sheldon Sloan  ¹⁰     Fabio Cataldi     Kevin Shan     Christopher J. Rabbat     Michael Chiorean  ¹¹     Douglas C. Wolf  ¹²     Bruce E. Sands  ¹³     Geert R. D'Haens  ¹⁴     Silvio Danese  ¹⁵     Martina Goetsch  ¹⁶     Brian G. Feagan  ^17    
1 University of California San Diego School of Medicine, San Diego, United States
² University Hospitals Leuven, Leuven, Belgium
³ University of Lorraine, Inserm, Nancy, France
⁴ Feinstein IBD Center, Mount Sinai, New York, United States
⁵ Hospital Clínic de Barcelona, IDIBAPS. CIBERehd, Barcelona, Spain
⁶ Cedars-Sinai Medical Center, Los Angeles, United States
⁷ GI Alliance Research, Southlake, United States
⁸ Az Delta, Roeselare, Belgium
⁹ University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
¹⁰ Arena Pharmaceuticals, a wholly-owned subsidiary of Pfizer Inc, New York, NY, USA, San Diego, United States
¹¹ IBD Center, Swedish Medical Center, Seattle, WA, United States
¹² Atlanta Gastroenterology Associates, Atlanta, United States
¹³ Icahn School of Medicine at Mount Sinai, New York, United States
¹⁴ University of Amsterdam, Amsterdam, Netherlands
¹⁵ IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
¹⁶ Arena Pharmaceuticals Development GmbH, a wholly-owned subsidiary of Pfizer Inc, New York, NY, USA, Zug, Switzerland
¹⁷ Alimentive Inc / University of Western Ontario, London, Canada

Topic
IBD, Nurses, Primary Care

Session
Clinical trials in ulcerative colitis I

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)